Warfarin pharmacogenomics

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 243-251

  Cavallari, Larisa H ^a   Limdi, Nita A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cytochrome P450 2C9; Genotype; Pharmacogenomics; Vitamin K epoxide reductase; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AFRICAN AMERICAN; ANTICOAGULANT THERAPY; ASIAN; BLEEDING; CAUCASIAN; CLINICAL TRIAL; DNA POLYMORPHISM; DOSE CALCULATION; DOSE RESPONSE; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENOMICS; RACE DIFFERENCE; REVIEW; TREATMENT RESPONSE;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 67650242330     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 133(6 Suppl):160S-198S.
2. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fbrillation. N Engl J Med (2003) 349(11):1019-1026.
3. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med (1994) 120(11): 897-902.
4. Wysowski DK, Nourjah P, Swartz L: Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med (2007) 167(13):1414-1419.
5. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2009) 113(4):784-792.
6. Uno T, Sugimoto K, Sugawara K, Tateishi T: The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. J Clin Pharm Ther (2008) 33(1):67-73.
7. FDA approves updated warfarin (Coumadin) prescribing information: FDA, Silver Spring, MD, USA (2007). www.fda.gov/bbs/ topics/NEWS/2007/ NEW01684.html
8. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R: Infuence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther (2002) 72(6):702-710.
9. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 52(4):447-450.
10. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC, Ng KS et al: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther (2006) 79(3):197-205.
11. Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, Higuchi S et al: Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit (2000) 22(3):237-244.
12. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G: Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther (2008) 84(6):722-728.
13. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identifcation and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 60(2):382-387.
14. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics (2004) 14(8):527-537.
15. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics (2005) 15(11):779-786.
16. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 352(22):2285-2293.
17. Au N, Rettie AE: Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev (2008) 40(2):355-375.
18. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P: Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2007) 121(1):23-34.
19. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics (2005) 15(10):687-691.
20. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N: VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 9(10):1445-1458.
21. Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther (2007) 81(5):742-747.
22. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W: Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 112(4):1013-1021.
23. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT: Infuence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 9(5):511-526.
24. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: Current status and future challenges. Pharmacogenomics J (2007) 7(2):99-111.
25. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353(9154):717- 719.
26. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc (2002) 287(13):1690-1698.
27. Lindh JD, Holm L, Andersson ML, Rane A: Infuence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol (2009) 65(4): 365-375.
28. Kealey C, Chen Z, Christie J, Thorn CF, Whitehead AS, Price M, Samaha FF, Kimmel SE: Warfarin and cytochrome P450 2C9 genotype: Possible ethnic variation in warfarin sensitivity. Pharmacogenomics (2007) 8(3):217-225.
29. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL et al: A genome-wide scan for common genetic variants with a large infuence on warfarin maintenance dose. Blood (2008) 112(4):1022-1027.
30. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther (2004) 75(3):204-212.
31. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 91(1):87-94.
32. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH: Factors infuencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 8(11):1535-1544.
33. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, Shearer MJ, Mumford AD: Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost (2008) 6(10):1663-1670.
34. Scott SA, Edelmann L, Kornreich R, Desnick RJ: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 82(2):495-500.
35. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2005) 105(2):645-649.
36. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood (2005) 106(7):2329-2333.
37. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA: Infuence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 79(4):291-302.
38. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aguilante CL et al: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 84(3):326-331.
39. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L et al: A genome-wide association study confrms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 5(3):e1000433.
40. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E: Combined genetic profles of components and regulators of thea vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost (2006) 95(2):205-211.
41. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V: The infuence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost (2006) 95(5):782-787.
42. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S et al: Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res (2007) 120(2):181-186.
43. Rieder MJ, Reiner AP, Rettie AE: γ-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost (2007) 5(11):2227-2234.
44. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F: APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics (2006) 16(8):609-611.
45. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS: Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J (2008) 8(1):53-60.
46. Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, Goh BC, Lee SC, Chowbay B: Infuence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol (2008) 65(2):260-264.
47. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR et al: CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 111(8):4106-4112.
48. The Intsernational HapMap Consortium: The International HapMap Project. Nature (2003) 426(6968):789-796.
49. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK: Evaluation of genetic factors for warfarin dose prediction. Clin Med Res (2007) 5(1):8-16.
50. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R Jr: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: Comparison with other equations. Pharmacogenomics (2008) 9(2):169-178.
51. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE: Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 84(3):332-339.
52. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the effcacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther (2008) 83(3):460-470.
53. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, Lee TH, Kuo CT, Sun FM, Chang YJ, Kuan PL et al: Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 84(1):83-89.
54. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF et al: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 116(22):2563-2570.
55. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM et al: Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients. Pharmacogenet Genomics (2009) 19(3):226-234.
56. Owen RP, Altman RB, Klein TE: PharmGKB and the International Warfarin Pharmacogenetics Consortium: The changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum Mutat (2008) 29(4):456-460.
57. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ et al: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 360(8):753-764.
58. Warfarin Dosing: Barnes-Jewish Hospital at Washinton University Medical Center, St Louis, MO, USA (2008). http://www.warfarindosing.org
59. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther (2005) 78(5):540-550.
60. Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A: Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther (2004) 76(5):409-417.
61. Schalekamp T, Brassé BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 80(1):13-22.
62. Schalekamp T, Brassé BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: Interaction between both genotypes affects dose requirement. Clin Pharmacol Ther (2007) 81(2):185-193.
63. Taube J, Halsall D, Baglin T: Infuence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 96(5):1816-1819.
64. Cavallari LH, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA: Predictors of unstable anticoagulation in African Americans. J Thromb Thrombolysis (2008):doi:10.1007./s11239-008-0236-8
65. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 358(10):999-1008.
66. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT: Infuence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (20080 83(2):312-321.
67. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G: Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 84(5):775-778.
68. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics (2004) 14(8):539-547.
69. Flockhart DA, O'Kane D, Williams MS, Watson MS; On Behalf of the ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 10(2):139-150.
70. Eckman MH, Rosand J, Greenberg SM, Gage BF: Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fbrillation. Ann Intern Med (2009) 150(2):73-83.
71. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM: Infuence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis (2009):doi.10.1016/j. bcmd.2009.01.019.
72. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M: Kidney function infuences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 20(4):912-921.